Pills

This is the text extract for Schedule Update - effective 1 May 2013 , browse documents here.


Pharmaceutical Management Agency

Update

New Zealand Pharmaceutical Schedule

Effective 1 May 2013

Section H cumulative for April and May 2013


Contents

Summary of PHARMAC decisions effective 1 May 2013 ................................ 3 Amendment to restrictions for ciprofloxacin tablets and clindamycin ........... 3 New brand of ACE inhibitor fully subsidised ................................................. 4 Tacrolimus – decision pending....................................................................... 5 Levonorgestrel tab 1.5 mg – Sole Subsidised Supply ..................................... 5 Pedialyte plain and fruit flavours to be discontinued .................................... 5 News in brief ................................................................................................. 5 Tender News .................................................................................................. 6 Looking Forward ........................................................................................... 6 Sole Subsidised Supply products cumulative to May 2013 ............................ 7 New Listings ................................................................................................ 19 Changes to Restrictions ............................................................................... 20 Changes to Subsidy and Manufacturer’s Price............................................. 22 Changes to General Rules............................................................................ 23 Changes to Brand Name ............................................................................. 25 Changes to Section I ................................................................................... 26 Delisted Items ............................................................................................. 27 Items to be Delisted .................................................................................... 29 Section H changes to Part II ........................................................................ 30 Index ........................................................................................................... 33

2


Summary of PHARMAC decisions

EFFECTIVE 1 MAY 2013 New listings (page 19) • Perindopril (Apo-Perindopril) tab 2 mg and 4 mg • Clonidine hydrochloride (Clonidine BNM) tab 25 mcg • Metolazone (Zaroxolyn) tab 5 mg – S29 – Special Authority – Retail pharmacy • Hydralazine hydrochloride (Onelink) tab 25 mg – S29 – Special Authority – Retail pharmacy • Lidocaine [lignocaine] hydrochloride (Lidocaine-Claris) inj 2%, 5ml and 2%, 20 ml • Pharmacy services (BSF Apo-Diltiazem CD) Brand switch fee Changes to restrictions (pages 20-21) • Perindopril (Coversyl) tab 2 mg and 4 mg – removal of higher subsidy by endorsement • Trandolapril (Gopten) cap 1 mg and 2 mg – rewording of higher subsidy by endorsement • Diltiazem hydrochloride (Apo-Diltiazem CD) cap long-acting 120 mg, 180 mg and 240 mg – addition of brand switch fee payable • Ciprofloxacin tab 250 mg, 500 mg and 750 mg – amendment to restriction • Clindamycin cap hydrochloride 150 mg and inj phosphate 150 mg per ml, 4 ml – amendment to restriction • Itraconazole cap 100 mg – amendment to restriction • Isoniazid tab 100 mg, tab 100 mg with rifampicin 150 mg and tab 150 mg with rifampicin 300 mg – amendment to restriction • Lignocaine hydrochloride to lidocaine [lignocaine] hydrochloride – amendment to chemical name Decreased subsidy (page 22) • Levonorgestrel (Postinor-1) tab 1.5 mg • Codeine phosphate (PSM) tab 15 mg, 30 mg and 60 mg • Amisulpride (Solian) tab 100 mg, 200 mg, 400 mg and oral liq 100 mg per ml Increased subsidy (page 22) • Perindopril (Coversyl) tab 2 mg and 4 mg

3


4 Pharmaceutical Schedule - Update News

Amendment to restrictions for ciprofloxacin tablets and clindamycin

Changes to the restrictions on some antibiotics were made last month (1 April 2013) to reflect proposed new prescribing rules in hospitals which will take effect from 1 July 2013. From 1 May 2013 these are being amended as follows: • For ciprofloxacin, the endorsement restriction will be removed from all tablet presentations and will be replaced by a prescribing guideline. • For clindamycin, the specified specialist type will be removed, but the Retail pharmacy-Specialist restriction will remain. These changes are being made to allow prescribers more time to implement appropriate changes to their prescribing practices and we will work with the sector to do this. Whilst this change doesn’t come into effect until 1 May 2013, we would encourage pharmacists to apply these changes to current prescriptions. Audit and Compliance at Sector Services are aware of PHARMACs recommendations. This will reduce the administrative burden for pharmacists

New brand of ACE inhibitor fully subsidised

Apo-Perindopril (perindopril tab 2 mg and 4 mg) will be fully subsidised from 1 May 2013. The higher subsidy by endorsement for the Coversyl brand for patients with congestive heart failure, who were taking perindopril prior to 1 June 1998, will be removed. From 1 May 2013 any patient currently receiving the higher subsidy by endorsement will need to switch to the Apo-Perindopril brand to remain on a fully subsidised product.


Pharmaceutical Schedule - Update News

5

Tacrolimus – decision pending

PHARMAC consulted on a proposal in December 2012 to list Sandoz’s brand of tacrolimus capsules from 1 March 2013. The proposal also proposed to award Sole Subsidised Supply Status (the only funded brand in the community) and Hospital Supply Status (the only available brand in DHB hospitals, subject to a 1% discretionary variance limit) to Tacrolimus Sandoz from 1 September 2013 to 31 August 2017. A decision has not yet been made by PHARMAC.

Levonorgestrel tab 1.5 mg – Sole Subsidised Supply

From 1 May 2013, the price and subsidy of Postinor-1 (levonorgestrel) 1.5 mg tablets will decrease and Sole Supply on this brand will commence 1 October 2013. The Next Choice brand (2 x 750 mcg tablets) will have a subsidy reduction from 1 July 2013 and be delisted on 1 October 2013.

Pedialyte plain and fruit flavours to be discontinued

The plain and fruit flavours of Pedialyte electrolyte solution are to be discontinued. The supplier, Abbott Laboratories, has notified this is due to a global discontinuation and would result in bubblegum being the only flavour listed in the Pharmaceutical Schedule. The date of discontinuation is yet to be confirmed.

News in brief

• The chemical name for lignocaine hydrochloride will be changed to lidocaine [lignocaine] hydrochloride from 1 May 2013. • A Brand Switch Fee will apply to dispensings of Apo-Diltiazem CD, diltazem hydrochloride long-acting 120 mg, 180 mg and 240 mg capsules from 1 May 2013 to 1 August 2013. • Phlexy 10 (aminoacid formula without phenylalanine) tropical sachets will be delisted 1 November 2013 due to supplier discontinuation. • From 1 May 2013, the price of the Home Essential brand of calamine cream 100 g will increase. The Pharmacy Health brand remains fully subsidised. • The brand name of Goldshield’s levothyroxine tab 50 mcg and 100 mcg will change from Goldshield to Mercury Pharma. • The Nupentin brand of gabapentin 400 mg capsule will be supplied in bottles instead of blisters. There is a new Pharmacode for the bottled packs and these will be subsidised from 1 May 2013. The 100 mg and 300 mg strengths of Nupentin changed to bottles from 1 September 2012. • Sodium cromoglycate (Rex) nasal spray, 4% will be delisted 1 November 2013 due to supplier discontinuation.


Tender News

Sole Subsidised Supply changes – effective 1 June 2013

Chemical Name Bezafibrate Diclofenac sodium Diclofenac sodium Domperidone Promethazine hydrochloride Oxycodone hydrochloride Presentation; Pack size Tab 200 mg; 90 tab Tab EC 25 mg; 100 tab Tab EC 50 mg; 500 tab Tab 10 mg; 100 tab Oral liq 5 mg per 5 ml; 100 ml Inj 50 mg per ml, 1 ml; 5 inj Sole Subsidised Supply brand (and supplier) Bezalip (Activis) Apo-Diclo (Apotex) Apo-Diclo (Apotex) Prokinex (Airflow) Allersoothe (AFT) OxyNorm (MundiPharm)

Looking Forward

This section is designed to alert both pharmacists and prescribers to possible future changes to the Pharmaceutical Schedule. It may also assist pharmacists, distributors and wholesalers to manage stock levels. Possible decisions for future implementation 1 June 2013 • Carbomer (Poly Gel) ophthalmic gel 0.2%, 30 x 0.5 g – new listing – Special Authority – Retail pharmacy • Hypromellose with dextran (Poly-Tears) eye drops 0.3% with dextran 0.1%, 15 ml OP – subsidy and price decrease, and reference pricing of Methopt and Vistil brands • Sodium hyaluronate (Hylo-Fresh) eye drops 1 mg per ml, 10 ml OP – new listing – Special Authority – Retail pharmacy • Ticagrelor (Brilinta) tab 90 mg – new listing – Special Authority – Retail Pharmacy

6


Sole Subsidised Supply Products – cumulative to May 2013

Generic Name

Abacavir sulphate Acarbose Acetazolamide Acetylcysteine Aciclovir Allopurinol Amantadine hydrochloride Aminophylline Amitriptyline Amlodipine Amoxycillin Amoxycillin clavulanate

Presentation

Oral liq 20 mg per ml Tab 300 mg Tab 50 mg and 100 mg Tab 250 mg Inj 200 mg per ml, 10 ml Tab dispersible 200 mg, 400 mg & 800 mg Tab 100 mg & 300 mg Cap 100 mg Inj 25 mg per ml, 10 ml Tab 10 mg Tab 25 mg & 50 mg Tab 2.5 mg Tab 5 mg & 10 mg Inj 250 mg, 500 mg & 1 g Cap 250 mg & 500 mg Grans for oral liq amoxycillin 125 mg with potassium clavulanate 31.25 mg per 5 ml Grans for oral liq amoxycillin 250 mg with potassium clavulanate 62.5 mg per 5 ml Tab 500 mg with potassium clavulanate 125 mg Crm Tab 100 mg Tab 100 mg Tab dispersible 300 mg Tab 50 mg & 100 mg Tab 10 mg, 20 mg, 40 mg & 80 mg Inj 600 mcg, 1 ml Tab 50 mg Inj 50 mg Tab 500 mg Tab 2.5 mg & 5 mg Inj 1.2 mega u per 2.3 ml Inj 600 mg Eye drops 0.5% Eye drops 0.25%

Brand Name Expiry Date*

Ziagen Ziagen Accarb Diamox Martindale Acetylcysteine Lovir Apo-Allopurinol Symmetrel DBL Aminophylline Arrow-Amitriptyline Amitrip Apo-Amlodipine Apo-Amlodipine Ibiamox Alphamox Augmentin Augmentin Curam Duo AFT Vitala-C Ethics Aspirin EC Ethics Aspirin Mylan Atenolol Zarator AstraZeneca Imuprine Imuran Apo-Azithromycin ArrowBendrofluazide Bicillin LA Sandoz Betoptic Betoptic S 2014 2014 2013 2013 2015 2015 2015 2013 2015 2014 2015 2014 2014 2014 2015 2014 2015 2013 2014 2014 2014 2014 2014 2014 2013 2015

Aqueous cream Ascorbic acid Aspirin Atenolol Atorvastatin Atropine sulphate Azathioprine Azithromycin Bendrofluazide Benzathine benzylpenicillin Benzylpenicillin sodium (Penicillin G) Betaxolol hydrochloride

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

7


Sole Subsidised Supply Products – cumulative to May 2013

Generic Name

Bezafibrate Bicalutamide Bisacodyl Bisoprolol fumarate Blood glucose diagnostic test meter Blood glucose diagnostic test strip Brimonidine tartrate Cabergoline Calamine Calcitonin Calcium carbonate Calcium folinate Candesartan Captopril Cefaclor monohydrate Cefazolin sodium Ceftriaxone sodium Cefuroxime sodium Cetomacrogol Cetirizine hydrochloride Chloramphenicol Chlorhexidine gluconate

Presentation

Tab long-acting 400 mg Tab 50 mg Tab 5 mg Tab 2.5 mg, 5 mg & 10 mg Meter with 50 lancets, a lancing device and 10 diagnostic test strips Blood glucose test strips Eye drops 0.2% Tab 0.5 mg Lotn, BP Inj 100 iu per ml, 1 ml Tab 1.25 g (500 mg elemental) Tab eff 1.75 g (1 g elemental) Tab 15 mg Tab 4 mg, 8 mg, 16 mg & 32 mg Tab 12.5 mg, 25 mg & 50 mg Oral liq 5 mg per ml Grans for oral liq 125 mg per 5 ml Inj 500 mg & 1 g Inj 500 mg Inj 1 g Inj 750 mg Crm BP Oral liq 1 mg per ml Tab 10 mg Eye oint 1% Eye drops 0.5% Mouthwash 0.2% Handrub 1% with ethanol 70% Soln 4% Nail-soln 8% Tab 0.5 mg, 2.5 mg & 5 mg Tab 5 mg with hydrochlorothiazide 12.5 mg Tab 250 mg, 500 mg & 750 mg Tab 20 mg

Brand Name Expiry Date*

Bezalip Retard Bicalaccord Lax-Tab Bosvate CareSens N CareSens N POP CareSens II CareSens CareSens N Arrow-Brimonidine Dostinex PSM Miacalcic Arrow-Calcium Calsource DBL Leucovorin Calcium Candestar m-Captopril Capoten Ranbaxy-Cefaclor AFT Veracol Aspen Ceftriaxone Multichem PSM Cetirizine - AFT Zetop Chlorsig Chlorafast healthE healthE Orion Apo-Ciclopirox Zapril Inhibace Plus Cipflox Arrow-Citalopram 2015 2014 2013 2013 2015

2015 2014 2015 2015 2014 2014 2014 2015 2013 2013 2014 2013 2014 2013 2014 2015 2015 2014 2015 2013 2013 2014 2014

Ciclopirox olamine Cilazapril Cilazapril with hydrochlorothiazide Ciprofloxacin Citalopram hydrobromide

8

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.


Sole Subsidised Supply Products – cumulative to May 2013

Generic Name

Clarithromycin Clindamycin Clomipramine hydrochloride Clonidine hydrochloride Clopidogrel Clotrimazole

Presentation

Tab 500 mg Tab 250 mg Cap hydrochloride 150 mg Tab 10 mg & 25 mg Tab 150 mcg Inj 150 mcg per ml, 1 ml Tab 75 mg Crm 1% Vaginal crm 1% with applicator Vaginal crm 2% with applicator Soln BP Tab 500 mcg Powder for soln for oral use 4.4 g Crm 10% Tab 50 mg Tab 50 mg Oral liq 100 mg per ml Tab 50 mg & 100 mg Tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tabs Nasal spray 10 mcg per dose Tab 1 mg & 4 mg Eye oint 0.1% Eye drops 0.1% Inj 4 mg per ml, 1 ml & 2 ml

Brand Name Expiry Date*

Apo-Clarithromycin Apo-Clarithromycin Clindamycin ABM Apo-Clomipramine Catapres Apo-Clopidogrel Clomazol Clomazol Clomazol Midwest Colgout Electral Itch-Soothe Nausicalm Cycloblastin Neoral Siterone Ginet 84 Desmopressin-PH&T Douglas Maxidex Maxidex Hospira Maxitrol Maxitrol 2014 2013 2015 2015 2013 2014 2013 2013 2013 2013 2015 2015 2013 2015 2015 2014 2014 2015 2014 2013 2013 2014

Coal tar Colchicine Compound electrolytes Crotamiton Cyclizine hydrochloride Cyclophosphamide Cyclosporin Cyproterone acetate Cyproterone acetate with ethinyloestradiol Desmopressin Dexamethasone

Dexamethasone sodium phosphate

Dexamethasone with neomycin Eye oint 0.1% with neomycin sulphate and polymyxin b sulphate 0.35% and polymyxin B sulphate 6,000 u per g Eye drops 0.1% with neomycin sulphate 0.35% and polymyxin B sulphate 6,000 u per ml Dexamphetamine sulphate Dextrose Dextrose with electrolytes Tab 5 mg Inj 50%, 10 ml Soln with electrolytes

PSM Biomed Pedialyte – Fruit Pedialyte – Bubblegum Pedialyte – Plain

2015 2014 2013

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

9


Sole Subsidised Supply Products – cumulative to May 2013

Generic Name

Diclofenac sodium

Presentation

Tab long-acting 75 mg & 100 mg Inj 25 mg per ml, 3 ml Eye drops 1 mg per ml Suppos 12.5 mg, 25 mg, 50 mg & 100 mg Tab long-acting 60 mg Cap long-acting 120 mg, 180 mg & 240 mg Tab 30 mg & 60 mg Tab long-acting 150 mg Cap 50 mg Cap 120 mg Tab 50 mg with total sennosides 8 mg Tab 2 mg & 4 mg Tab 100 mg Oint BP Tab 5 mg, 10 mg & 20 mg Inj 20 mg, 40 mg, 60 mg, 80 mg, 100 mg, 120 mg & 150 mg Tab 200 mg Inj 500 mcg per ml, 1 ml Tab 10 mg & 20 mg Tab 200 mg Tab 10 mcg Tab 20 mcg with levonorgestrel 100 mcg & 7 inert tab Tab 30 mcg with levonorgestrel 150 mcg & 7 inert tab Tab 25 mg Tab long-acting 5 mg & 10 mg Tab long-acting 2.5 mg Transdermal patch 12.5 mcg per hour, 25 mcg per hour, 50 mcg per hour, 75 mcg per hour, 100 mcg per hour Inj 50 mcg per ml, 2 ml & 10 ml Oral liq 30 mg per 1 ml (6 mg elemental per 1 ml) Inj 300 mcg per 0.5 ml Inj 480 mcg per 0.5 ml

Brand Name Expiry Date*

Diclax SR Voltaren Voltaren Ophtha Voltaren DHC Continus Apo-Diltiazem CD Dilzem Pytazen SR Laxofast 50 Laxofast 120 Laxsol Apo-Doxazosin Doxine AFT m-Enalapril Clexane Entapone DBL Ergometrine Loxalate Arrow-Etidronate NZ Medical and Scientific Ava 20 ED Ava 30 ED Aromasin Plendil ER Plendil ER Mylan Fentanyl Patch 2014 2015 2013 2014 2014 2013 2014 2014 2014 2015 2015 2015 2014 2013 2015 2015 2014 2015 2014

Dihydrocodeine tartrate Diltiazem hydrochloride

2013 2015

Dipyridamole Docusate sodium Docusate sodium with sennosides Doxazosin mesylate Doxycycline hydrochloride Emulsifying ointment Enalapril Enoxaparin sodium Entacapone Ergometrine maleate Escitalopram Etidronate disodium Ethinyloestradiol Ethinyloestradiol with levonorgestrel

Exemestane Felodopine Fentanyl

Fentanyl citrate Ferrous sulphate Filgrastim

Boucher and Muir Ferodan Zarzio Zarzio

2015 2013

31/12/15

10

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.


Sole Subsidised Supply Products – cumulative to May 2013

Generic Name

Finasteride Flucloxacillin sodium

Presentation

Tab 5 mg Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Cap 250 mg & 500 mg Inj 250 mg, 500 mg & 1 g Cap 50 mg, 150 mg & 200 mg Eye drops 0.1% Crm 5% Cap 20 mg Tab dispersible 20 mg, scored Tab 250 mg Metered aqueous nasal spray, 50 mcg per dose Tab 500 mg Tab 40 mg Inj 10 mg per ml, 2 ml Crm 2% Oint 2% Tab 600 mg Inj 40 mg per ml, 2 ml Tab 80 mg Tab 5 mg Suppos 3.6 g Liquid Aerosol spray 400 mcg per dose TDDS 5 mg & 10 mg Tab 600 mcg Inj 5 mg per ml, 1 ml Oral liq 2 mg per ml Tab 500 mcg, 1.5 mg & 5 mg Tab 5 mg & 20 mg Crm 1% Powder Inj 50 mg per ml, 1 ml Rectal foam 10%, CFC-Free (14 applications) Lipocream 0.1% Milky emul 0.1% Oint 0.1% Scalp lotn 0.1% Crm 1% with miconazole nitrate 2%

Brand Name Expiry Date*

Rex Medical AFT Staphlex Flucloxin Ozole Flucon Efudix Fluox Fluox Flutamin Flixonase Hayfever & Allergy Urex Forte Diurin 40 Frusemide-Claris Foban Foban Lipazil Pfizer Apo-Gliclazide Minidiab PSM healthE Glytrin Nitroderm TTS Lycinate Serenace Serenace Serenace Douglas Pharmacy Health ABM Solu-Cortef Colifoam Locoid Lipocream Locoid Crelo Locoid Locoid Micreme H 2014 2015 2014 2014 2015 2015 2013 2013 2015 2015 2013 2013 2013 2015 2014 2015 2015 2013 2014

Fluconazole Fluorometholone Fluorouracil sodium Fluoxetine hydrochloride Flutamide Fluticasone propionate Furosemide

Fusidic acid Gemfibrozil Gentamicin sulphate Gliclazide Glipizide Glycerol Glyceryl trinitrate

Haloperidol

2013

Hydrocortisone

2015 2014 2013 2015 2015

Hydrocortisone acetate Hydrocortisone butyrate

Hydrocortisone with miconazole

2013

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

11


Sole Subsidised Supply Products – cumulative to May 2013

Generic Name

Hydrocortisone with wool fat and mineral oil Hydroxocobalamin Hydroxychloroquine sulphate Hyoscine N-butylbromide Ibuprofen

Presentation

Lotn 1% with wool fat hydrous 3% and mineral oil Inj 1 mg per ml, 1 ml Tab 200 mg Inj 20 mg, 1 ml Tab 10 mg Tab 200 mg Tab long-acting 800 mg Oral liq 100 mg per 5 ml Crm 5% Tab 2.5 mg Aqueous nasal spray, 0.03%, 15 ml OP Nebuliser soln, 250 mcg per ml, 1 ml & 2 ml Inj 50 mg per ml, 2 ml Tab 100 mg Tab 20 mg Tab long-acting 40 mg Cap 10 mg & 20 mg Cap 100 mg Shampoo 2% Oral liq 10 g per 15 ml Tab 100 mg Oral liq 10 mg per ml Tab 150 mg Cap 15 mg & 30 mg Eye drops 50 mcg per ml Tab 2.5 mg Subdermal implant (2 x 75 mg rods) Viscous soln 2% Inj 1%, 5 ml & 20 ml Crm 2.5% with prilocaine 2.5% (5 g tubes) Crm 2.5% with prilocaine 2.5%; 30 g OP Tab 5 mg, 10 mg & 20 mg Tab 250 mg & 400 mg Cap 250 mg

Brand Name Expiry Date*

DP Lotn HC ABM Hydroxocobalamin Plaquenil Buscopan Gastrosoothe Arrowcare Brufen SR Fenpaed Aldara Dapa-Tabs Univent Univent Ferrum H PSM Ismo 20 Corangin Oratane Itrazole Sebizole Laevolac Zetlam 3TC 3TC Solox Hysite Letraccord Jadelle Xylocaine Viscous Xylocaine EMLA EMLA Arrow-Lisinopril Lithicarb FC Douglas 2015 2015 2014 2014 2015 2014 2015 2013 2014 2013 2014 2013 2015 2015 2015 31/12/13 2014 2013 2013 2014 2015 2015 2014 2014 2013 2014 2013 2013

Imiquimod Indapamide Ipratropium bromide

Iron polymaltose Isoniazid Isosorbide mononitrate Isotretinoin Itraconazole Ketoconazole Lactulose Lamivudine

Lansoprazole Latanoprost Letrozole Levonorgestrel Lignocaine hydrochloride Lignocaine with prilocaine

Lisinopril Lithium carbonate

12

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.


Sole Subsidised Supply Products – cumulative to May 2013

Generic Name

Lodoxamide trometamol Loperamide hydrochloride Loratadine

Presentation

Eye drops 0.1% Cap 2 mg Oral liq 1 mg per ml Tab 10 mg Tab 1 mg & 2.5 mg Tab 12.5 mg, 25 mg, 50 mg & 100 mg Tab 50 mg with hydrochlorothiazide 12.5 mg Powder 13.125 g, sachets Liq 0.5% Shampoo 1% Size 2 Tab 100 mg Tab 135 mg Tab 160 mg Tab 4 mg & 100 mg Inj 40 mg per ml Inj 40 mg per ml with lignocaine 1 ml Tab 50 mg Enema 1 g per 100 ml Suppos 500 mg Tab immediate-release 500 mg & 850 mg Oral liq 2 mg per ml Oral liq 5 mg per ml Oral liq 10 mg per ml Tab 5 mg Inj 25 mg per ml, 2 ml & 20 ml Inj 40 mg per ml, 1 ml; 62.5 mg per ml, 2 ml; 500 mg & 1 g Inj 5 mg per ml, 2 ml Tab 10 mg Tab long-acting 23.75 mg, 47.5 mg, 95 mg & 190 mg Inj 1 mg per ml, 5 ml Tab 50 mg & 100 mg Tab long-acting 200 mg

Brand Name Expiry Date*

Lomide Diamide Relief Lorapaed Loraclear Hayfever Relief Ativan Lostaar Arrow-Losartan & Hydroclorothiazide Lax-Sachets A-Lices A-Lices EZ-fit Paediatric Mask De-Worm Colofac Apo-Megestrol Medrol Depo-Medrol Depo-Medrol with Lidocaine Purinethol Pentasa Asacol Apotex Biodone Biodone Forte Biodone Extra Forte Methatabs Hospira Solu-Medrol Pfizer Metamide Metoprolol-AFT CR Lopresor Lopresor Slow-Lopresor 2014 2013 2013

Lorazepam Losartan Losartan with hydrochlorothiazide Macrogol 3350 Malathion Mask for spacer device Mebendazole Mebeverine hydrochloride Megestrol acetate Methylprednisolone Methylprednisolone acetate Methylprednisolone acetate with lignocaine Mercaptopurine Mesalazine Metformin hydrochloride Methadone hydrochloride

2013 2014 2014 2014 2013 2015 2014 2014 2015 2015 2015 2015 2013 2015 2014 2015 2015 2013 2013 2015 2014 2015 2015

Methotrexate Methylprednisolone sodium succinate Metoclopramide hydrochloride Metoprolol succinate Metoprolol tartrate

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

13


Sole Subsidised Supply Products – cumulative to May 2013

Generic Name

Miconazole Miconazole nitrate Mirtazapine Moclobemide Mometasone furoate Morphine hydrochloride Morphine sulphate

Presentation

Oral gel 20 mg per g Crm 2% Tab 30 mg & 45 mg Tab 150 mg & 300 mg Crm 0.1% Oint 0.1% Oral liq 1 mg per ml, 2 mg per ml, 5 mg per ml & 10 mg per ml Inj 5 mg per ml, 1 ml Inj 10 mg per ml, 1 ml Inj 15 mg per ml, 1 ml Inj 30 mg per ml, 1 ml Tab long-acting 10 mg, 30 mg, 60 mg & 100 mg Cap long-acting 10 mg, 30 mg, 60 mg & 100 mg

Brand Name Expiry Date*

Decozol Multichem Avanza Apo-Moclobemide m-Mometasone RA-Morph DBL Morphine Sulphate DBL Morphine Sulphate DBL Morphine Sulphate DBL Morphine Sulphate Arrow-Morphine LA m-Elson Hospira Konsyl-D Naphcon Forte Apo-Nadolol Noflam 250 Noflam 500 Naltraccord AstraZeneca Nevirapine Alphapharm Habitrol Habitrol Habitrol Apo-Nicotinic Acid Arrow-Norfloxacin Noriday 28 Primolut N Nilstat Nilstat Nilstat Octreotide Max Rx 2014 2014 2015 2014 2014 2013 2014 2013 2013 2014 2015 2015 2013 2014 2015 2014 2015 2014 2015 2015 2015 2015 2014

2013

Morphine tartrate Mucilaginous laxatives Naphazoline hydrochloride Nadolol Naproxen Naltrexone hydrochloride Neostigmine Nevirapine Nicotine

Inj 80 mg per ml, 1.5 ml & 5 ml Dry Eye drops 0.1% Tab 40 mg & 80 mg Tab 250 mg Tab 500 mg Tab 50 mg Inj 2.5 mg per ml, 1 ml Tab 200 mg Gum 2 mg & 4 mg (classic, fruit, mint) Lozenge 1 mg & 2 mg Patch 7 mg, 14 mg & 21 mg Tab 50 mg & 500 mg Tab 400 mg Tab 350 mcg Tab 5 mg Oral liq 100,000 u per ml Cap 500,000 u Tab 500,000 u Inj 50 mcg per ml, 1 ml Inj 100 mcg per ml, 1 ml Inj 500 mcg per ml, 1 ml

Nicotinic acid Norfloxacin Norethisterone Nystatin

Octreotide (somatostatin analogue)

14

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.


Sole Subsidised Supply Products – cumulative to May 2013

Generic Name

Oil in water emulsion Omeprazole

Presentation

Crm Cap 10 mg, 20 mg & 40 mg Powder Inj 40 mg Tab disp 8 mg Tab 4 mg & 8 mg

Brand Name Expiry Date*

healthE Fatty Cream Omezol Relief Midwest Dr Reddy’s Omeprazole Dr Reddy’s Ondansetron Dr Reddy’s Ondansetron Ox-Pam Oxycodone Orion Syntometrine Pamidronate BNM Pantocid IV Dr Reddy’s Pantoprazole Paracare Parafast Ethics Paracetamol Paracare Double Strength Paracetamol + Codeine (Relieve) Lacri-Lube Loxamine Breath-Alert Permax Lyderm A-Scabies PSM DBL Pethidine Hydrochloride DBL Pethidine Hydrochloride PSM Cilicaine VK AFT AFT Pizaccord 2015 2015 2014

Ondansetron

2013

Oxazepam Oxycodone hydrochloride Oxytocin Pamidronate disodium Pantoprazole

Tab 10 mg & 15 mg Inj 10 mg per ml, 1 ml & 2 ml Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml Inj 3 mg per ml, 10 ml; 6 mg per ml, 10 ml & 9 mg per ml, 10 ml Inj 40 mg Tab 20 mg & 40 mg Suppos 500 mg Tab 500 mg Oral liq 120 mg per 5 ml Oral liq 250 mg per 5 ml Tab paracetamol 500 mg with codeine phosphate 8 mg Eye oint with soft white paraffin Tab 20 mg Low range & normal range Tab 0.25 mg & 1 mg Crm 5% Lotn 5% Tab 50 mg & 100 mg Inj 50 mg per ml, 1 ml Inj 50 mg per ml, 2 ml

2014 2015 2015 2014 2014 2013 2015 2014

Paracetamol

Paracetamol with codeine Paraffin liquid with soft white paraffin Paroxetine hydrochloride Peak flow meter Pergolide Permethrin Pethidine hydrochloride

2014 2013 2013 2015 2014 2014 2015 2014

Phenobarbitone Phenoxymethylpenicillin (Pencillin V)

Tab 15 mg & 30 mg Cap potassium salt 250 mg & 500 mg Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Tab 15 mg, 30 mg & 45 mg

2015 2013

Pioglitazone

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

15


Sole Subsidised Supply Products – cumulative to May 2013

Generic Name

Pizotifen Poloxamer Potassium chloride Pramipexole hydrochloride Pravastatin Procaine penicillin Promethazine hydrochloride Pyridostigmine bromide Pyridoxine hydrochloride Quinapril with hydrochlorothiazide

Presentation

Tab 500 mcg Oral drops 10% Tab long-acting 600 mg Tab 0.125 mg & 0.25 mg Tab 20 mg & 40 mg Inj 1.5 mega u Tab 10 mg & 25 mg Tab 60 mg Tab 25 mg Tab 50 mg Tab 10 mg with hydrochlorothiazide 12.5 mg Tab 20 mg with hydrochlorothiazide 12.5 mg Oral liq 150 mg per 10 ml Tab 150 mg & 300 mg Cap 150 mg Tab 100 mg Tab orodispersible 10 mg Tab 0.25 mg, 1 mg, 2 mg & 5 mg Tab 150 mg & 300 mg Nebuliser soln, 1 mg per ml & 2 mg per ml, 2.5 ml Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per vial, 2.5 ml Tab 50 mg & 100 mg Tab 25 mg, 50 mg & 100 mg Tab 10 mg Tab 20 mg Tab 40 mg Tab 80 mg Inj 23.4%, 20 ml Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml Grans effervescent 4 g sachets Eye drops 2%

Brand Name Expiry Date*

Sandomigran Coloxyl Span-K Dr Reddy’s Pramipexole Cholvastin Cilicaine Allersoothe Mestinon PyridoxADE Apo-Pyridoxine Accuretic 10 Accuretic 20 Peptisoothe Arrow-Ranitidine Mycobutin Norvir Rizamelt Ropin ArrowRoxithromycin Asthalin Duolin 2014 2013 2015 2014 2013 2015 2015 2015 2015 2014 2015 2013 2014 2014 2015 2014 2014 2015

Ranitidine hydrochloride Rifabutin Ritonavir Rizatriptan Ropinirole hydrochloride Roxithromycin Salbutamol Salbutamol with ipratropium bromide Sertraline Sildenafil Simvastatin

Arrow-Sertraline Silagra Arrow-Simva 10mg Arrow-Simva 20mg Arrow-Simva 40mg Arrow-Simva 80mg Biomed Micolette Ural Rexacrom

2013 2014 2014

Sodium chloride Sodium citrate with sodium lauryl sulphoacetate Sodium citro-tartrate Sodium cromoglycate

2013 2013 2013 2013

16

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.


Sole Subsidised Supply Products – cumulative to May 2013

Generic Name

Spacer device

Presentation

800 ml 230 ml (single patient) Tab 25 mg & 100 mg Inj 12 mg per ml, 0.5 ml Tab 50 mg & 100 mg Tab 20 mg Cap 400 mcg Soln 2.3% with triethanolamine lauryl sulphate and fluorescein sodium, 500 ml & 1,000 ml Tab 10 mg Cap 5 mg, 20 mg, 100 mg & 250 mg Tab 1 mg, 2 mg & 5 mg Tab 250 mg Inj long-acting 100 mg per ml, 10 ml Cap 40 mg Tab 25 mg Inj 250 mcg Inj 1 mg per ml, 1 ml Eye drops 0.25% & 0.5% Eye drops 0.3% Eye oint 0.3% Inj 40 mg per ml, 2 ml Tab 100 mg Cap 50 mg Inj 10 mg per ml, 1 ml Inj 40 mg per ml, 1 ml Crm 0.02% Oint 0.02% 0.1% in Dental Paste USP Tab 500 mg Eye drops 0.5% & 1% Cap 250 mg Inj 500 mg Tab 40 mg & 80 mg Tab, strong, BPC Tab (BPC cap strength)

Brand Name Expiry Date*

Volumatic Space Chamber Plus Spirotone Arrow-Sumatriptan Arrow-Sumatriptan Genox Tamsulosin-Rex Pinetarsol 2015

Spironolactone Sumatriptan Tamoxifen citrate Tamsulosin hydrochloride Tar with triethanolamine lauryl sulphate and fluorescein Temazepam Temozolomide Terazosin hydrochloride Terbinafine Testosterone cypionate Testosterone undecanoate Tetrabenazine Tetracosactrin Timolol maleate Tobramycin

2013 2013 2014 2013 2014

Normison Temaccord Arrow Dr Reddy’s Terbinafine Depo-Testosterone Andriol Testocaps Motetis Synacthen Synacthen Depot Arrow-Timolol Tobrex Tobrex DBL Tobramycin Tasmar Arrow-Tramadol Kenacort-A Kenacort-A40 Aristocort Aristocort Oracort Cyklokapron Mydriacyl Ursosan Mylan Isoptin B-PlexADE MultiADE

2014 2013 2013 2014 2014 2015 2013 2014 2014 2014

Tolcapone Tramadol hydrochloride Triamcinolone acetonide

2014 2014 2014

Tranexamic acid Tropicamide Ursodeoxycholic acid Vancomycin hydrochloride Verapamil hydrochloride Vitamin B complex Vitamins

2013 2014 2014 2014 2014 2013 2013

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

17


Sole Subsidised Supply Products – cumulative to May 2013

Generic Name

Zidovudine [AZT] Zidovudine [AZT] with lamivudine Zinc and castor oil Zinc sulphate May changes in bold

Presentation

Cap 100 mg Oral liq 10 mg per ml Tab 300 mg with lamivudine 150 mg Oint BP Caps 137.4 mg (50 mg elemental)

Brand Name Expiry Date*

Retrovir Retrovir Alphapharm Multichem Zincaps 2013 2014 2014 2014

18

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New Listings

Effective 1 May 2013

52 57 58 61 119 PERINDOPRIL ❋ Tab 2 mg ................................................................................. 3.75 ❋ Tab 4 mg ................................................................................. 4.80 CLONIDINE HYDROCHLORIDE ❋ Tab 25 mcg............................................................................. 15.09 METOLAZONE – Special Authority see SA1323 – Retail pharmacy Tab 5 mg ............................................................................. CBS 30 30 112 50 ✔ Apo-Perindopril ✔ Apo-Perindopril ✔ Clonidine BNM ✔ Zaroxolyn S29 ✔ Onelink S29 ✔ Lidocaine-Claris ✔ Lidocaine-Claris ✔ BSF Apo-Diltiazem CD

HYDRALAZINE HYDROCHLORIDE – Special Authority see SA1321 – Retail pharmacy ❋ Tab 25 mg ........................................................................... CBS 56 LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE Inj 2%, 5 ml – Up to 5 inj available on a PSO .............................. 6.90 Inj 2%, 20 ml – Up to 5 inj available on a PSO ............................ 2.40 PHARMACY SERVICES – May only be claimed once per patient Brand switch fee ....................................................................... 4.33 The Pharmacode for BSF Apo-Diltiazem CD is 2437775 25 1 1 fee

186

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

19


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions

Effective 1 May 2013

52 PERINDOPRIL Perindopril will be funded to the level of the ex-manufacturer price listed in the Schedule for patients who were taking these ACE inhibitors for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". Definition of Congestive Heart Failure At the request of some prescribers the PTAC Cardiovascular subcommittee has provided a definition of congestive heart failure for the purposes of the funding of the manufacturer’s surcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for the funding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requires or has in the past required concomitant treatment with a diuretic. The definition could also be considered to include patients post myocardial infarction with an ejection fraction of less than 40%." ❋ Tab 2 mg – Higher subsidy of $18.50 per 30 tab with Endorsement .................................................................. 3.75 30 ✔ Apo-Perindopril (18.50) Coversyl ❋ Tab 4 mg – Higher subsidy of $25.00 per 30 tab with Endorsement .................................................................. 4.80 30 ✔ Apo-Perindopril (25.00) Coversyl TRANDOLAPRIL Higher subsidy by endorsement is available Trandolapril will be funded to the level of the ex-manufacturer price listed in the Schedule for patients who were taking these ACE inhibitors trandolapril for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". Definition of Congestive Heart Failure At the request of some prescribers the PTAC Cardiovascular subcommittee has provided a definition of congestive heart failure for the purposes of the funding of the manufacturer's surcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for the funding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requires or has in the past required concomitant treatment with a diuretic. The definition could also be considered to include patients post myocardial infarction with an ejection fraction of less than 40%." For the purposes of this endorsement, congestive heart failure includes patients post myocardial infarction with an ejection fraction of less than 40%. Patients who started on trandolapril after 1 June 1998 are not eligible for full subsidy by endorsement. ❋ Cap 1 mg – Higher subsidy of $18.67 per 28 cap with Endorsement .................................................................. 3.06 28 (18.67) Gopten ❋ Cap 2 mg – Higher subsidy of $27.00 per 28 cap with Endorsement .................................................................. 4.43 28 (27.00) Gopten DILTIAZEM HYDROCHLORIDE ❋ Cap long-acting 120 mg – Brand switch fee payable (Pharmacode 2437775) .......... 31.83 ❋ Cap long-acting 180 mg – Brand switch fee payable (Pharmacode 2437775) .......... 47.67 ❋ Cap long-acting 240 mg – Brand switch fee payable (Pharmacode 2437775) .......... 63.58

52

57

500 500 500

✔ Apo-Diltiazem CD ✔ Apo-Diltiazem CD ✔ Apo-Diltiazem CD

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

20

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 May 2013 (continued)

91 CIPROFLOXACIN – Subsidy by endorsement 1) Subsidised only if: a) Patient has: i) microbiologically confirmed and clinically significant pseudomonas infection; or ii) prostatitis; or iii) pyelonephritis; or iv) gonorrhoea; b) Prescription or PSO is written by, or on the recommendation of, an infectious disease physician or a clinical microbiologist; and 2) The prescription or PSO is endorsed accordingly. Recommended for patients with the any of the following: i) microbiologically confirmed and clinically significant pseudomonas infection; or ii) prostatitis; or iii) pyelonephritis; or iv) gonorrhoea; or Tab 250 mg – Up to 5 tab available on a PSO ............................ 2.20 28 ✔ Cipflox Tab 500 mg – Up to 5 tab available on a PSO ............................ 3.00 28 ✔ Cipflox 10.71 100 ✔ Cipflox Tab 750 mg .............................................................................. 5.15 28 ✔ Cipflox 5.52 30 ✔ Ciprofloxacin Rex CLINDAMYCIN Cap hydrochloride 150 mg – Maximum of 4 cap per prescription; can be waived by endorsement – Retail pharmacy-Specialist .... 9.90 16 ✔ Clindamycin ABM Specialist must be an infectious disease physician or a clinical microbiologist Inj phosphate 150 mg per ml, 4 ml – Retail pharmacy-Specialist...160.00 10 ✔ Dalacin C Prescriptions must be written by, or on the recommendation of, an infectious disease physician or a clinical microbiologist. ITRACONAZOLE Cap 100 mg – Subsidy by endorsement .................................... 4.25 15 ✔ Itrazole Funded for tinea vesicolor where topical treatment has not been successful and diagnosis has been confirmed by mycology, or for tinea unguium where terbinafine has not been successful in eradication or the patient is intolerant to terbinafine and diagnosis has been confirmed by mycology and the prescription is endorsed accordingly. Can be waived by endorsement - Retail pharmacy - Specialist. Specialist must be an infectious disease physician, clinical microbiologist, clinical immunologist or dermatologist. ISONIAZID – Retail pharmacy-Specialist a) No patient co-payment payable b) Prescriptions must be written by, or on the recommendation of, an internal medicine physician, paediatrician, clinical microbiologist, dermatologist or public health physician ❋ Tab 100 mg ........................................................................... 20.00 100 ✔ PSM ❋ Tab 100 mg with rifampicin 150 mg ....................................... 90.04 100 ✔ Rifinah ❋ Tab 150 mg with rifampicin 300 mg ..................................... 179.57 100 ✔ Rifinah LIGNOCAINE HYDROCHLORIDE LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE Viscous soln 2%...................................................................... 55.00 200 ml Inj 1%, 5 ml – Up to 5 inj available on a PSO ........................... 35.00 50 Inj 2%, 5 ml – Up to 5 inj available on a PSO ........................... 23.00 50 6.90 25 Inj 1%, 20 ml – Up to 5 inj available on a PSO .......................... 20.00 5 Inj 2%, 20 ml – Up to 5 inj available on a PSO .......................... 15.00 5 2.40 1 ✔ Xylocaine Viscous ✔ Xylocaine ✔ Xylocaine ✔ Lidocaine-Claris ✔ Xylocaine ✔ Xylocaine ✔ Lidocaine-Claris

92

94

96

119

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

21


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer’s Price

Effective 1 May 2013

52 PERINDOPRIL ( subsidy) Tab 2 mg ................................................................................. 3.75 (18.50) Tab 4 mg .................................................................................. 4.80 (25.00) CALAMINE ( price) a) Only on a prescription b) Not in combination Crm, aqueous, BP .................................................................... 1.77 (3.80) LEVONORGESTREL ( subsidy) ❋ Tab 1.5 mg ............................................................................... 3.50 a) Maximum of 2 tab per prescription b) Up to 5 tab available on a PSO 30 Coversyl 30 Coversyl

66

100 g Home Essential 1 ✔ Postinor-1

78

120

CODEINE PHOSPHATE ( subsidy) – Safety medicine; prescriber may determine dispensing frequency Tab 15 mg ................................................................................ 4.75 100 ✔ PSM Tab 30 mg ................................................................................ 5.80 100 ✔ PSM Tab 60 mg .............................................................................. 12.50 100 ✔ PSM AMISULPRIDE ( subsidy) – Safety medicine; prescriber may determine dispensing frequency Tab 100 mg .............................................................................. 6.22 30 ✔ Solian Tab 200 mg ........................................................................... 21.92 60 ✔ Solian Tab 400 mg ........................................................................... 44.52 60 ✔ Solian Oral liq 100 mg per ml ............................................................ 52.50 60 ml ✔ Solian

132

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

22

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to General Rules

Effective 1 May 2013

18 3.3 Original Packs, Certain Antibiotics and Unapproved Medicines 3.3.2 If a Community Pharmaceutical is either: a) the liquid oral form of an antibiotic to which a diluent must be added by the Contractor at the time of dispensing; or b) an unapproved medicine supplied under Section 29 of the Medicines Act 1981 excluding any medicine listed as Cost, Brand, Source of Supply, and it is prescribed or ordered by a Practitioner in an amount that does not coincide with the amount contained in one or more standard packs of that Community Pharmaceutical, Subsidy will be paid for the amount prescribed or ordered by the Practitioner in accordance with either clause 3.1 or clause 3.3 of the Schedule, and for the balance of any pack or packs from which the Community Pharmaceutical has been dispensed. At the time of dispensing the Contractor must keep a record of the quantity discarded. To ensure wastage is reduced, the Contractor should reduce the amount dispensed to make it equal to the quantity contained in a whole pack where: a) the difference the amount dispensed and the amount prescribed by the Practitioner is less than 10% (eg; if a prescription is for 105 mls then a 100 ml pack would be dispensed); and b) in the reasonable opinion of the Contractor the difference would not affect the efficacy of the course of treatment prescribed by the Practitioner. Note: For the purposes of audit and compliance it is an act of fraud to claim wastage and then use the wastage amount for any subsequent prescription.

Effective 1 April 2013

13 “Hospital Pharmacy-Specialist” means that the Community Pharmaceutical is not eligible for Subsidy unless it is supplied by a hospital or pharmacy contracted to the Funder to dispense as a hospital pharmacy to an Outpatient either: a) on a Prescription signed by a Specialist, or b) where the treatment with the Community Pharmaceutical has been recommended by a Specialist, on the Prescription of a practitioner which is either: i) endorsed with the words “recommended by [name of specialist and year of authorisation]” and signed by the Practitioner, or ii) endorsed with the word ‘protocol’ which means “initiated in accordance with DHB hospital approved protocol”, iii) annotated by the dispensing pharmacist, following verbal confirmation from the Practitioner of the name of the Specialist and date of recommendation, with the words “recommended by [name of specialist and date of authorisation], confirmed by [practitioner]”. Where the Contractor has an electronic record of such an Endorsement or Annotation from a previous prescription for the same Community Pharmaceutical written by a prescriber for the same patient, they may annotate the prescription accordingly. “As recommended by a Specialist” to be interpreted as either: 1) a) follows a substantive consultation with an appropriate Specialist; b) the consultation to relate to the Patient for whom the Prescription is written; c) consultation to mean communication by referral, telephone, letter, facsimile or email; d) except in emergencies consultation to precede annotation of the Prescription; and e) both the specialist and the General Practitioner must keep a written record of the consultation; or 2) treatment with the Community Pharmaceutical has been initiated in accordance with a DHB hospital approved protocol

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

23


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to General Rules – effective 1 April 2013 (continued)

15 “Retail Pharmacy-Specialist” means that the Community Pharmaceutical is only eligible for Subsidy if it is either: a) supplied on a Prescription or Practitioner’s Supply Order signed by a Specialist, or, b) in the case of treatment recommended by a Specialist, supplied on a Prescription or Practitioner’s Supply Order and either: i) endorsed with the words “recommended by [name of Specialist and year of authorisation]” and signed by the Practitioner, or ii) endorsed with the word ‘protocol’ which means “initiated in accordance with DHB hospital approved protocol”, or iii) Annotated by the dispensing pharmacist, following verbal confirmation from the Practitioner of the name of the Specialist and date of recommendation, with the words “recommended by [name of specialist and year of authorisation], confirmed by [practitioner]”. Where the Contractor has an electronic record of such an Endorsement or Annotation from a previous prescription for the same Community Pharmaceutical written by a prescriber for the same patient, they may annotate the prescription accordingly. “As recommended by a Specialist” to be interpreted as either: 1) a) follows a substantive consultation with an appropriate Specialist; b) the consultation to relate to the Patient for whom the Prescription is written; c) consultation to mean communication by referral, telephone, letter, facsimile or email; d) except in emergencies consultation to precede annotation of the Prescription; and e) both the Specialist and the General Practitioner must keep a written record of consultation; or 2) treatment with the Community Pharmaceutical has been initiated in accordance with a DHB hospital approved protocol.

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

24

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Brand Name

Effective 1 May 2013

85 LEVOTHYROXINE Tab 50 mcg .............................................................................. 1.71 28 ✔ Goldshield Mercury Pharma ✔ Goldshield Mercury Pharma

‡ Safety cap for extemporaneously compounded oral liquid preparations. Tab 100 mcg............................................................................. 1.78 28 ‡ Safety cap for extemporaneously compounded oral liquid preparations.

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

25


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Section I

Effective 1 May 2013

224 INFLUENZA VACCINE – Hospital pharmacy [Xpharm] Inj ........................................................................................... 90.00 A) ✔ Fluarix ✔ Fluvax is available each year for patients who meet the following criteria, as set by PHARMAC: a) all people 65 years of age and over; b) people under 65 years of age with who: i) have the following cardiovascular disease: 1) ischaemic heart disease, 2) congestive heart disease, 3) rheumatic heart disease, 4) congenital heart disease, or 5) cerebo-vascular disease; ii) have the following chronic respiratory disease: 1) asthma, if on a regular preventative therapy, or 2) other chronic respiratory disease with impaired lung function; iii)are children aged four and under who have been hospitalised for respiratory illness or have a history of significant respiratory illness. iii)iv) have diabetes; iv)v) have chronic renal disease; v)vi) have any cancer, excluding basal and squamous skin cancers if not invasive; vi)vii)have any of the following other conditions: a) autoimmune disease, b) immune suppression, c) HIV, d) transplant recipients, e) neuromuscular and CNS diseases, f) haemoglobinopathies, or g) are children on long term aspirin; or vii)h)are pregnancy pregnant. c) people under 18 years of age living within the boundaries of the Canterbury District Health Board d) are children aged four and under who have been hospitalised for respiratory illness or have a history of significant respiratory illness Unless meeting other the criteria above, the following conditions are excluded from funding: a) asthma not requiring regular preventative therapy, b) hypertension and/or dyslipidaemia without evidence of end-organ disease. Doctors are the only Contractors entitled to claim payment from the Funder for the supply of influenza vaccine to patients eligible under the above criteria for subsidised immunisation and they may only do so in respect of the influenza vaccine listed in the Pharmaceutical Schedule. Individual DHBs may fund patients over and above the above criteria. The claiming process for these additional patients should be determined between the DHB and Contractor. Stock of the seasonal influenza vaccine is typically available from February until late July with suppliers being required to ensure supply until at least 30 June. Exact start and end dates for each season will be notified each year. 10

B) C) D)

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

26

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Delisted Items

Effective 1 May 2013

24 CALCIUM CARBONATE WITH AMINOACETIC ACID ❋ Tab 420 mg with aminoacetic acid 180 mg – Higher subsidy of $6.30 per 100 tab with Endorsement ......................................................................... 3.00 100 (6.30) Titralac Additional subsidy by endorsement is available for pregnant women. The prescription must be endorsed accordingly. MICONAZOLE Oral gel 20 mg per g ................................................................ 4.95 (8.70) RIVAROXABAN – Special Authority see SA1066 – Retail pharmacy Tab 10 mg ............................................................................ 306.00 DILTIAZEM HYDROCHLORIDE Cap long-acting 120 mg ............................................................ 1.91 (4.34) Cap long-acting 180 mg ........................................................... 2.86 (6.50) Cap long-acting 240 mg ........................................................... 3.81 (8.67) SILDENAFIL – Special Authority see SA1293 – Retail pharmacy Tab 25 mg ............................................................................. 39.00 Tab 50 mg ............................................................................. 43.50 Tab 100 mg – For sildenafil oral liquid formulation refer, page 179 ............................................................................. 47.00 CALCIPOTRIOL Oint 50 mcg per g .................................................................. 20.20 Soln 50 mcg per ml ................................................................ 33.79 4 4 4 30 g OP 60 ml OP 40 g OP Daktarin 30 ✔ Xarelto

40

47 57

Cardizem CD Cardizem CD Cardizem CD ✔ Viagra ✔ Viagra ✔ Viagra ✔ Daivonex ✔ Daivonex

63

72

89

AZITHROMYCIN – Maximum of 5 days treatment per prescription; can be waived by endorsement For Endorsement, patient has either: i) Received a lung transplant and requires treatment or prophylaxis for bronchiolitis obliterans syndrome *; or ii) Cystic fibrosis and has chronic infection with Pseudomonas aeruginosa or Pseudomonas related gram negative organisms * Indications marked with * are Unapproved Indications Tab 500 mg – Up to 8 tab available on a PSO ............................ 1.25 2 OP ✔ Arrow-Azithromycin PAMIDRONATE DISODIUM Inj 3 mg per ml, 10 ml ............................................................ 16.00 (37.50) Inj 6 mg per ml, 10 ml ............................................................ 32.00 (75.00) Inj 9 mg per ml, 10 ml ............................................................ 48.00 (112.50) 1 Pamisol 1 Pamisol 1 Pamisol

113

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

27


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Delisted Items – effective 1 May 2013 (continued)

185 212 TYLOXAPOL ❋ Eye drops 0.25% ..................................................................... 8.63 15 ml OP ✔ Enuclene ✔ Neocate Advance

AMINO ACID FORMULA – Special Authority see SA1219 – Hospital pharmacy [HP3] Powder (tropical) .................................................................... 53.00 400 g OP

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

28

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Items to be Delisted

Effective 1 August 2013

186 PHARMACY SERVICES - May only be claimed once per patient ❋ Brand switch fee........................................................................ 4.33 1 fee ✔ BSF Apo-Diltiazem CD

Effective 1 November 2013

181 211 SODIUM CROMOGLYCATE Nasal spray, 4% ..................................................................... 15.85 22 ml OP ✔ Rex

AMINOACID FORMULA WITHOUT PHENYLALANINE – Special Authority see SA1108 – Hospital pharmacy [HP3] Sachets (tropical) ................................................................. 324.00 30 ✔ Phlexy 10

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

29


Section H page ref

Price (ex man. excl. GST) $ Per

Brand or Generic Manufacturer

Section H changes to Part II

Effective 1 May 2013

16 AMISULPRIDE ( price and addition of HSS) Tab 100 mg – 1% DV Jul-13 to 2016 ........................................ 6.22 Tab 200 mg – 1% DV Jul-13 to 2016 ...................................... 21.92 Tab 400 mg – 1% DV Jul-13 to 2016 ...................................... 44.52 Oral liq 100 mg per ml – 1% DV Jul-13 to 2016 ...................... 52.50 AMOXYCILLIN (delisting) Drops 100 mg per ml ................................................................ 4.00 Note – Ospamox drops 100 mg per ml to be delisted from 1 July 2013 CEFOTAXIME (delisting) Inj 2 g ....................................................................................... 2.60 Note – Cefotaxime Sandoz inj 2 g to be delisted from 1 July 2013 CLONIDINE HYDROCHLORIDE Tab 25 mcg – 1% DV Jul-13 to 2015 ...................................... 15.09 Note – Dixarit tab 25 mcg to be delisted 1 July 2013 CODEINE PHOSPHATE ( price and addition of HSS) Tab 15 mg – 1% DV Jul-13 to 2016 .......................................... 4.75 Tab 30 mg – 1% DV Jul-13 to 2016 .......................................... 5.80 Tab 60 mg – 1% DV Jul-13 to 2016 ........................................ 12.50 DORIPENEM (delisting) Vial for infusion 500 mg ....................................................... 454.50 Note – Doribax vial for infusion 500 mg to be delisted from 1 July 2013 LEVONORGESTREL Tab 1.5 mg – 1% DV Jul-13 to 2016 ......................................... 3.50 Note – Next Choice tab 750 mcg to be delisted 1 July 2013 30 60 60 60 ml 30 ml Solian Solian Solian Solian Ospamox

17

22

1

Cefotaxime Sandoz

25

112

Clonidine BNM

26

100 100 100 10

PSM PSM PSM Doribax

29

42

1

Postinor-1

42

LIGNOCAINE HYDROCHLORIDE LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE (amended chemical name) Pump spray 10%, 50 ml CFC-free – 1% DV Nov-10 to 2013 .................................................... 75.00 50 ml Xylocaine Viscous soln 2% – 1% DV Sep-11 to 2014 .............................. 55.00 200 ml Xylocaine Viscous Inj 1%, 2 ml ............................................................................ 57.60 50 Xylocaine Inj 1%, 5 ml ............................................................................. 35.00 50 Xylocaine Inj 1%, 5 ml – 1% DV Jul-13 to 2015 ........................................ 8.75 25 Lidocaine-Claris Inj 1%, 20 ml .......................................................................... 20.00 5 Xylocaine Inj 1%, 20 ml – 1% DV Jul-13 to 2015 ...................................... 2.40 1 Lidocaine-Claris Inj 2%, 2 ml ............................................................................ 62.40 50 Xylocaine Inj 2%, 5 ml ............................................................................. 23.00 50 Xylocaine Inj 2%, 5 ml – 1% DV Jul-13 to 2015 ........................................ 6.90 25 Lidocaine-Claris Inj 2%, 20 ml .......................................................................... 15.00 5 Xylocaine Inj 2%, 20 ml – 1% DV Jul-13 to 2015 ...................................... 2.40 1 Lidocaine-Claris Note – Xylocaine inj 1% 2 ml, 1% 5 ml, 1% 20 ml, 2% 2 ml, 2% 5 ml, 2% 20 ml to be delisted 1 July 2013. MICONAZOLE NITRATE (delisting) Powder 2%................................................................................ 8.50 Note – Daktarin powder 2% to be delisted from 1 July 2013 Products with Hospital Supply Status (HSS) are in bold. Expiry date of HSS period is 30 June of the year indicated unless otherwise stated 30 g Daktarin

46

30


Section H page ref

Price (ex man. excl. GST) $ Per

Brand or Generic Manufacturer

Section H changes to Part II – effective 1 May 2013 (continued)

7 MORPHINE SULPHATE (delisting) Inj 1 mg per ml, 30 ml prefilled syringe ................................... 75.00 10 Note - Biomed inj 1 mg per ml, 30 ml prefilled syringe to be delisted from 1 July 2013. PERINDOPRIL Tab 2 mg .................................................................................. 3.75 Tab 4 mg .................................................................................. 4.80 30 30 Biomed

52

Apo-Perindopril Apo-Perindopril Diprivan

55

PROPOFOL (delisting) Inj 2%, 50 ml prefilled syringe .................................................. 60.00 1 Note – Diprivan Inj 2%, 50 ml prefilled syringe to be delisted from 1 July 2013. RETINOL PALMITATE (delisting) Oint 25 g .................................................................................. 2.00 Oint 50 g .................................................................................. 2.86 Note – PSM and healthE oint 25 g and 50 g to be delisted from 1 July 2013. 1 1

57

PSM healthE

61

SODIUM HYALURONATE (amendment to line item description) Ophthalmic inj 14 mg per ml, 0.55 ml – 1% DV Oct-12 to 2015 ..................................................... 50.00 1 Healon GV Ophthalmic inj 14 mg per ml, 0.85 ml – 1% DV May-13 to 2015 ................................................... 50.00 1 Healon GV Note – Clarification of line description with a new Pharmacode applied to the new presentation. SORBOLENE WITH GLYCERIN ( price) Crm with 10% glycerine, 100 g ................................................. 2.72 Crm with 10% glycerine, 500 ml ............................................... 5.46 1 1 healthE healthE

61

Effective 1 April 2013

18 19 19 24 BACLOFEN ( price and addition of HSS) Tab 10 mg - 1% DV Jun-13 to 2016.......................................... 3.85 BENZBROMARONE Tab 100 mg ............................................................................ 45.00 BISMUTH TRIOXIDE Tab 120 mg ............................................................................ 32.50 CHLORTHALIDONE (delisting) Tab 25 mg ................................................................................ 4.80 Note – Igroton tab 25 mg to be delisted from 1 June 2013 DIAZOXIDE Cap 25 mg ............................................................................ 110.00 Cap 100 mg .......................................................................... 280.00 100 100 112 30 Pacifen Benzbromaron De-Nol Igroton

28

100 100

Proglicem Proglicem

Products with Hospital Supply Status (HSS) are in bold. Expiry date of HSS period is 30 June of the year indicated unless otherwise stated

31


Section H page ref

Price (ex man. excl. GST) $ Per

Brand or Generic Manufacturer

Section H changes to Part II – effective 1 April 2013 (continued)

29 DOCETAXEL (new listing and change to HSS) Inj 20 mg – 1% DV Sep-11 to 30 April 2013 ............................ 48.75 Inj 20 mg – 1% DV May-13 to 2014 ........................................ 48.75 Inj 80 mg – 1% DV Sep-11 to 30 April 2013 .......................... 195.00 Inj 80 mg – 1% DV May-13 to 2014 ...................................... 195.00 GLYCERYL TRINITRATE Oint 0.2% ................................................................................ 22.00 HIGH FAT LOW CARBOHYDRATE FORMULA Powder (vanilla) (amendment to brand name) .......................... 35.50 Powder (unflavoured) .............................................................. 35.50 NITAZOXANIDE Tab 500 mg ........................................................................ 1680.00 NORTRIPTYLINE HYDROCHLORIDE ( price and addition of HSS) Tab 10 mg - 1% DV Jun-13 to 2016.......................................... 4.00 Tab 25 mg - 1% DV Jun-13 to 2016.......................................... 9.00 OXYBUTYNIN (addition of HSS) Tab 5 mg - 1% DV Jun-13 to 2016 ( price)............................ 11.20 Oral liq 5 mg per 5 ml - 1% DV Jun-13 to 2016 ( price) ......... 56.45 PARA-AMINO SALICYLIC ACID Grans for oral liq 4 g sachet ................................................... 280.00 PAROMOMYCIN Cap 250 mg .......................................................................... 126.00 PEGASPARGASE Inj 3,750 IU per 5 ml........................................................... 3,005.00 PROTIONAMIDE Tab 250 mg .......................................................................... 305.00 STIRIPENTOL Cap 250 mg .......................................................................... 509.29 Powder for oral liq 250 mg sachet ......................................... 509.29 TETRACYCLINE Cap 500 mg ............................................................................ 46.00 1 1 1 1 30g 300 g 300 g 30 100 180 500 473 ml 30 16 1 100 60 60 30 Docetaxel Ebewe Docetaxel Sandoz Docetaxel Ebewe Docetaxel Sandoz Rectogesic KetoCal 4:1 KetoCal 3:1 Alinia Norpress Norpress Apo-Oxybutynin Apo-Oxybutynin Paser Humatin Oncaspar Peteha Diacomit Diacomit Tetracyclin Wolff

37 37

50 50

52

53 53 53 56 63

63

Products with Hospital Supply Status (HSS) are in bold. Expiry date of HSS period is 30 June of the year indicated unless otherwise stated

32


Index

Pharmaceuticals and brands A Alinia ................................................................. 32 Amino acid formula ............................................ 28 Aminoacid formula without phenylalanine ........... 29 Amisulpride.................................................. 22, 30 Amoxycillin ........................................................ 30 Apo-Diltiazem CD ............................................... 20 Apo-Oxybutynin ................................................. 32 Apo-Perindopril ...................................... 19, 20, 31 Arrow-Azithromycin ........................................... 27 Azithromycin ...................................................... 27 B Baclofen ............................................................ 31 Benzbromaron ................................................... 31 Benzbromarone .................................................. 31 Bismuth trioxide ................................................. 31 BSF Apo-Diltiazem CD .................................. 19, 29 C Calamine............................................................ 22 Calcipotriol......................................................... 27 Calcium carbonate with aminoacetic acid ........... 27 Cardizem CD ...................................................... 27 Cefotaxime......................................................... 30 Cefotaxime Sandoz ............................................ 30 Chlorthalidone .................................................... 31 Cipflox ............................................................... 21 Ciprofloxacin ...................................................... 21 Ciprofloxacin Rex ............................................... 21 Clindamycin ....................................................... 21 Clindamycin ABM............................................... 21 Clonidine BNM ............................................. 19, 30 Clonidine hydrochloride ................................ 19, 30 Codeine phosphate ...................................... 22, 30 Coversyl ...................................................... 20, 22 D Daivonex ............................................................ 27 Daktarin ....................................................... 27, 30 Dalacin C ........................................................... 21 De-Nol ............................................................... 31 Diacomit ............................................................ 32 Diazoxide ........................................................... 31 Diltiazem hydrochloride ................................ 20, 27 Diprivan ............................................................. 31 Docetaxel ........................................................... 32 Docetaxel Ebewe ................................................ 32 Docetaxel Sandoz............................................... 32 Doribax .............................................................. 30 Doripenem ......................................................... 30 E Enuclene ............................................................ 28 F Fluarix ................................................................ 26 Fluvax ................................................................ 26 G Glyceryl trinitrate ................................................ 32 Gopten ............................................................... 20 H Healon GV.......................................................... 31 High fat low carbohydrate formula ...................... 32 Home Essential .................................................. 22 Humatin ............................................................. 32 Hydralazine hydrochloride .................................. 19 I Igroton ............................................................... 31 Influenza vaccine................................................ 26 Isoniazid ............................................................ 21 Itraconazole ....................................................... 21 Itrazole ............................................................... 21 K KetoCal 3:1 ........................................................ 32 KetoCal 4:1 ........................................................ 32 L Levonorgestrel ............................................. 22, 30 Levothyroxine .................................................... 25 Lidocaine-Claris ..................................... 19, 21, 30 Lidocaine [lignocaine] hydrochloride ...... 19, 21, 30 Lignocaine hydrochloride ............................. 21, 30 M Metolazone ........................................................ 19 Miconazole ........................................................ 27 Miconazole nitrate .............................................. 30 Morphine sulphate.............................................. 31 N Neocate Advance ............................................... 28 Nitazoxanide ...................................................... 32 Norpress ............................................................ 32 Nortriptyline hydrochloride.................................. 32 O Oncaspar ........................................................... 32 Ospamox ........................................................... 30 Oxybutynin ......................................................... 32 P Pacifen .............................................................. 31 Pamidronate disodium ....................................... 27 Pamisol ............................................................. 27 Para-amino salicylic acid.................................... 32 Paromomycin .................................................... 32 Paser ................................................................. 32 Pegaspargase .................................................... 32 Perindopril ....................................... 19, 20, 22, 31 Peteha ............................................................... 32 Pharmacy services....................................... 19, 29 Phlexy 10........................................................... 29 Postinor-1.................................................... 22, 30

33


Index

Pharmaceuticals and brands Proglicem .......................................................... 31 Propofol ............................................................. 31 Protionamide...................................................... 32 R Rectogesic......................................................... 32 Retinol palmitate ................................................ 31 Rifinah ............................................................... 21 Rivaroxaban ....................................................... 27 S Sildenafil ............................................................ 27 Sodium cromoglycate ........................................ 29 Sodium hyaluronate ........................................... 31 Solian .......................................................... 22, 30 Sorbolene with glycerin ...................................... 31 Stiripentol .......................................................... 32 T Tetracycline ....................................................... 32 Tetracyclin Wolff ................................................ 32 Titralac .............................................................. 27 Trandolapril ........................................................ 20 Tyloxapol ........................................................... 28 V Viagra ................................................................ 27 X Xarelto ............................................................... 27 Xylocaine ..................................................... 21, 30 Xylocaine Viscous ........................................ 21, 30 Z Zaroxolyn ........................................................... 19

34


Index

Pharmaceuticals and brands

35


Index

Pharmaceuticals and brands

36


Pharmaceutical Management Agency Level 9, 40 Mercer Street, PO Box 10-254, Wellington 6143, New Zealand Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - www.pharmac.govt.nz Freephone Information line (9am-5pm weekdays) 0800 66 00 50 ISSN 1172-9376 (Print) ISSN 1179-3686 (Online)

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the Update.

If Undelivered, Return To: PO Box 10-254, Wellington 6143, New Zealand

Metadata

Title

Schedule Update - effective 1 May 2013

Abstract

Pharmaceutical Management Agency Update New Zealand Pharmaceutical Schedule Effective 1 May 2013 Section H cumulative for April and May 2013 Contents Summary of PHARMAC decisions effective 1 May 2013 ….. 3 Amendment to restrictions for ciprofloxacin tablets and clindamycin …..…

Page 1

icon

Note

This text has been extracted from the source PDF document.

Also available as plain text.

Please contact webmaster to discuss alternative format options.